CSL

View our library:

NEWS & INSIGHTS (incl. Key Themes, Latest Interviews, Recent Reg. Guidance)

• Notable Theme (Commercial): US-Japan Tariffs: Informal US confirmation of a 15% tariff for pharma imports from Japan as part of a bilateral trade deal has caused confusion given the apparent lack of official US communication.
• Notable Theme (Commercial): DTC Advertising Impact: The FDA crackdown on DTC advertising raises a new commercial barrier. The industry spent $10.8bn on DTC advertising in the US in 2024, with AbbVie as the leading pharma advertiser.
• Notable Theme (Regulatory): EU Critical Medicines Act: It may include investigational products and mandatory redistribution measures, giving industry a chance to respond before legislation is finalized.

EDITORIAL CONTENTS (incl. Podcasts, Webinars)

• Notable Podcast: China Innovative Drugs And Commercial Insurance
• Notable Webinar: ICH GCP E6(R3): Navigating the New Era of Good Clinical Practice (October 24, 2025)
• Notable Webinar: Cliffhanger: Portfolio Tactics to Scale the $300bn Patent Cliff (October 29, 2025)

DEALS & FINANCING (incl. M&As, Licensing, Financing)

• Notable M&A: Genmab to Acquire Merus for $8B
• Notable Licensing: Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases totalling $5.3B
• Notable Financing: Crystalys Therapeutis Gets $205M in Series A Round

KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)

• Notable Analysis: Akeso | Idafang | NSCLC (Phase 3): “HARMONi Update Shows Potential OS Gains in Western Patients but Regulatory Path for Idafang Remains Unclear…”
• Notable Analysis: uniQure | AMT-130 | Huntington's Disease (Phase 2): “AMT-130 emerges as a groundbreaking therapy targeting the root cause of Huntington’s disease with positive results across all clinical endpoints…”
• Notable Analysis: Eli Lilly | Orforglipron | Type-2 Diabetes (Phase 3): “Eli Lilly’s oral non-peptide GLP-1 agonist orforglipron shows superiority to competitor Novo Nordisk’s oral Rybelsus in type 2 diabetes…”

RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)

• Notable Report: Key Potential Drug Launches in 2026
• Notable Report: Obesity and GLP-1 Dealmaking: Strategic Trends and Market Signals
• Notable Report: The Annual Clinical Trials Roundup, 2025 Edition: Innovation, Regulation, and Preservation
• Notable Report: The Evolution of Health Literacy: Challenges, Opportunities for Trial Recruitment in the Digital Age
• Notable Report: Working backwards: Patient access strategy is now guiding R&D
• Notable Report: Dealmaking Quarterly Statistics, Q2 2025
• Notable Report: Financing Quarterly Statistics, Q2 2025
• Notable Report: Patient-based Forecast: Obesity
• Notable Report: Epidemiology Forecast: Chronic Urticaria
• Notable Report: Epidemiology & Patient-based Forecast: Sickle Cell Disease
• Notable Report: Epidemiology & Patient-based Forecast: Pancreatic Cancer
• Notable Report: Obesity KOL Interview – US/UK/Germany
• Notable Report: Depression KOL Interview - Germany

Note: Require research support on scientific meetings not under below list? Submit your inquiry via Ask the Analyst!